The international summit on genome editing kicked off on Tuesday at the headquarters of the National Academy of Sciences, Washington, D.C. Several scientists and researchers gathered for the three-day conference that will discuss the scientific, ethical and governance issues associated with human gene-editing technologies.
The summit particularly focuses on whether gene editing of human embryos for therapeutic reasons should be considered or ruled out altogether, The Guardian noted.
“The overriding question is when, if ever, we will want to use gene editing to change human inheritance," summit chair David Baltimore of Caltech said in his introductory remarks. “We are close to altering human heredity and we need to decide how we as a society are going to use this capability.”
According to The Australian, the process fixing defecting genes is very complicated, so much so that it has slowed down the development of genetic therapies. With gene editing technology, scientists use molecular tools to repair or replace a defective gene or delete it.
A new tool called CRISPR-Cas9 has been adopted by laboratories worldwide as it is faster, economical, and simple enough to use with minimal level of training. Scientists hope to use the tool for diseases like sickle cell, fixing the defective gene in someone's own blood-producing cells instead of implanting donated ones.
Jennifer Doudna of the University of California at Berkeley is one of the pioneers of the CRISPR technology. Doudna told reporters that it will still take several years before the tool can be used for treatment of human diseases, The Washington Post reported.
"We don't understand enough yet about the human genome, and how genes interact, and which genes give rise to certain traits to edit for human enhancement today," she said.
Marcy Darnovsky of the Center for Genetics and Society advocacy group, however, opposes heritable gene editing and calls it potentially a "society-altering technology."


Is dark chocolate healthier than milk chocolate? 2 dietitians explain
PDG Explores $1 Billion Sale of China Data Center Assets
Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership
Salesforce Q1 FY2027 Earnings Beat Expectations Despite Soft Q2 Revenue Outlook
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
TrumpRx Expands Discount Drug Access With 600 Generic Medications 



